Overview

Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Allergic Conjunctivitis.

Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to establish the safety and efficacy of ketotifen/naphazoline ophthalmic solution compared to vehicle and its individual components in alleviating the signs and symptoms of conjunctival allergen challenge (CAC)-induced allergic conjunctivitis.
Phase:
Phase 3
Details
Lead Sponsor:
Bausch & Lomb Incorporated
Treatments:
Ketotifen
Naphazoline
Ophthalmic Solutions
Pharmaceutical Solutions